How to Test Human-Specific Combination Immunotherapies In Vivo

Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.

Humanized Mouse Model Head to Head: hPBMC vs hCD34+

Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity

Antigen-specific T cells, stimulation, enrichment and analysis, Miltenyi Biotec

How to Test Human-Specific Combination Immunotherapies In Vivo

Beginners Guide to PBMC Humanized Tumor Models

Frontiers Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research

A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses - ScienceDirect

Antibody–drug conjugates: in search of partners of choice: Trends in Cancer

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier, Cancer Cell International

Two is better than one: combining bispecific antibodies for signal 1 and signal 2

Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Cancers, Free Full-Text